0
0This research study identifies a novel mTORC1-independent pathway that explains why TSC2 gene mutations cause more severe liver disease than TSC1 mutations in Tuberous Sclerosis Complex (TSC) patients. While both defects lead to the hyperactivation of the protein mTORC1, the researchers discovered that a lack of TSC2 creates an abundance of uncomplexed-TSC1, which triggers a specific chemical chain reaction. This unique axis involving KDM5A, METTL3, and GYS2 significantly increases glycogen storage in the liver, a process that accelerates the development of tumors and lesions. Experiments on mouse and cellular models demonstrate that traditional treatments targeting only mTORC1 are insufficient because they do not address this secondary pathway. Consequently, the authors suggest that a combination therapy inhibiting both mTORC1 and the protein METTL3 could restore metabolic balance. These findings offer a more precise medical approach for patients who are currently resistant to standard clinical interventions.
References:
Yue X, Zhang Y, Zhao N, et al. Uncomplexed-TSC1 deploys novel mTORC1-independent pathway to exacerbate the liver glycogen storage in TSC[J]. Cell Death & Disease, 2025, 16(1): 829.
